Cogent Biosciences, Inc. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

Rang in aandelen #3334
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aandeelprijs
$30.11
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$5.22B
Verandering (1 dag)
2.00%
Verandering (1 jaar)
85.64%
Land
US
Handel Cogent Biosciences, Inc. (COGT)

Categorie

Healthcare
Dividendrendementgeschiedenis voor Cogent Biosciences, Inc. (COGT)
Het dividendrendement (TTM) van Cogent Biosciences, Inc. (aandelsymbool: COGT) per 2023-12-31 is: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Cogent Biosciences, Inc. (COGT) van 2015 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL